2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Obesity
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Fatty Liver
1
Burkitt Lymphoma
1
Interventions
Metformin
152
Clomiphene
52
Letrozole
41
Inositol
35
Folic Acid
18
Progesterone
17
Exercise
17
Ethinyl Estradiol
13
Estradiol
13
Chorionic Gonadotropin
13
Caloric Restriction
13
drospirenone and ethinyl estradiol combination
12
Contraceptives, Oral
12
cetrorelix
11
Pioglitazone
10
High-Intensity Interval Training
10
Cholecalciferol
10
Triptorelin Pamoate
9
Tablets
9
Spironolactone
9
Menotropins
8
Diet
8
Vitamin D
7
Thioctic Acid
7
Surveys and Questionnaires
7
Liraglutide
7
Gonadotropins
7
Acupuncture Therapy
7
follitropin alfa
6
drospirenone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Polycystic Ovary Syndrome
×
penclomedine
×
Clear all
NCT02157974
2024-06-04
APPLE
University of Colorado, Denver
Phase 2/3
Completed
92 enrolled
17 charts